Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself as a key player in the biotechnology sector, focusing on developing treatments for cancer and rare diseases. Under the leadership of CEO Dr. Vuong Trieu, the company is leveraging artificial intelligence and nanomedicine to innovate in biotechnology.
The company's intellectual property portfolio includes approximately 500 patent applications and 75 granted patents. Oncotelic is specifically targeting difficult-to-treat cancers such as glioblastoma and pancreatic cancer, along with rare pediatric disorders, addressing significant unmet medical needs in these areas.
Oncotelic Therapeutics (OTCQB: OTLC) si sta affermando come un attore chiave nel settore della biotecnologia, concentrandosi sullo sviluppo di terapie per il cancro e per malattie rare. Sotto la guida del CEO Dr. Vuong Trieu, l’azienda sfrutta l’intelligenza artificiale e la nanomedicina per innovare nel campo biotecnologico.
Il portafoglio di proprietà intellettuale comprende circa 500 domande di brevetto e 75 brevetti concessi. Oncotelic mira specificamente a tumori difficili da trattare come il glioblastoma e il cancro al pancreas, insieme a disturbi pediatrici rari, affrontando significativi bisogni medici insoddisfatti in queste aree.
Oncotelic Therapeutics (OTCQB: OTLC) se posiciona como un actor clave en el sector de biotecnología, centrando su trabajo en desarrollar tratamientos para el cáncer y enfermedades raras. Bajo el liderazgo del CEO Dr. Vuong Trieu, la compañía está aprovechando la inteligencia artificial y la nanomedicina para innovar en biotecnología.
Su portafolio de propiedad intelectual incluye aproximadamente 500 solicitudes de patente y 75 patentes concedidas. Oncotelic se dirige específicamente a cánceres de difícil tratamiento como el glioblastoma y el cáncer de páncreas, junto con trastornos pediátricos raros, abordando necesidades médicas no atendidas en estas áreas.
Oncotelic Therapeutics (OTCQB: OTLC)은 생명공학 분야의 핵심 플레이어로 자리매김하고 있으며, 암과 희귀 질환 치료제 개발에 중점을 두고 있습니다. CEO Dr. Vuong Trieu의 지도하에 이 회사는 인공지능과 나노의학을 활용해 생명공학 분야의 혁신을 이끌고 있습니다.
회사의 지적 재산 포트폴리오에는 약 500건의 특허 출원과 75건의 특허가 허가되었습니다가 포함되어 있습니다. Oncotelic은 글리오블라스트종(glioblastoma)과 췌장암처럼 치료가 어려운 암들, 그리고 희귀 소아 질환에 특히 집중하며, 이 분야의 중요한 미충족 의학적 필요를 다루고 있습니다.
Oncotelic Therapeutics (OTCQB: OTLC) se positionne comme un acteur clé du secteur biotechnologique, en se concentrant sur le développement de traitements pour le cancer et les maladies rares. Sous la direction du PDG Dr. Vuong Trieu, l’entreprise exploite l’intelligence artificielle et la nanomédecine pour innover en biotechnologie.
Le portefeuille de propriété intellectuelle de l’entreprise comprend environ 500 demandes de brevet et 75 brevets délivrés. Oncotelic cible spécifiquement les cancers difficiles à traiter tels que le gliome (glioblastome) et le cancer du pancréas, ainsi que des troubles pédiatriques rares, répondant ainsi à des besoins médicaux importants non satisfaits dans ces domaines.
Oncotelic Therapeutics (OTCQB: OTLC) positioniert sich als Schlüsselakteur im Biotech-Sektor und fokussiert sich auf die Entwicklung von Behandlungen für Krebs und seltene Krankheiten. Unter der Führung des CEO Dr. Vuong Trieu nutzt das Unternehmen künstliche Intelligenz und Nanomedizin, um in der Biotechnologie zu innovieren.
Das Portfolio an geistigem Eigentum umfasst etwa 500 Patentanmeldungen und 75 erteilte Patente. Oncotelic richtet sich speziell an schwer behandelbare Krebsarten wie Glioblastom und Bauchspeicheldrüsenkrebs sowie an seltene pädiatrische Erkrankungen und bedient damit einen großen ungedeckten medizinischen Bedarf in diesen Bereichen.
Oncotelic Therapeutics (OTCQB: OTLC) يعزز موقعه كلاعب رئيسي في قطاع التكنولوجيا الحيوية، مع تركيزه على تطوير علاجات للسرطان والأمراض النادرة. تحت قيادة المدير التنفيذي Dr. Vuong Trieu، تستفيد الشركة من الذكاء الاصطناعي والنانومديسين للابتكار في علم التكنولوجيا الحيوية.
محفظة الملكية الفكرية للشركة تتضمن حوالي 500 طلب براءة اختراع و75 براءة ممنوحة. تستهدف Oncotelic بشكل خاص سرطانات صعبة العلاج مثل الورم النخاعي النجمي (glioblastoma) وسرطان البنكرياس، إلى جانب اضطرابات نادرة لدى الأطفال، مع تلبية احتياجات طبية كبيرة غير مُلبَّاة في هذه المجالات.
Oncotelic Therapeutics (OTCQB: OTLC) 正在定位自己为生物技术领域的关键参与者，专注于癌症和罕见疾病的治疗开发。在 CEO Dr. Vuong Trieu 的领导下，该公司利用人工智能和纳米医学在生物技术领域进行创新。
公司知识产权组合包含大约500项专利申请和75项已授权专利。Oncotelic 还特别瞄准如胶质母细胞瘤（glioblastoma）和胰腺癌等难以治疗的癌症，以及罕见的儿科疾病，努力满足这些领域的显著未被满足的医疗需求。
- Strong intellectual property portfolio with 500 patent applications and 75 granted patents
- Diversified technological approach combining AI and nanomedicine
- Focus on high-unmet-need areas including glioblastoma and pancreatic cancer
- Early-stage development with no mentioned approved products
- Trading on OTCQB market, indicating lower tier exchange listing
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Advancing Cancer Research Brings New Hope for Patients Worldwide,” please visit: https://nnw.fm/pQ4wW
Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on young patients each year.
Against this backdrop of significant unmet need, Oncotelic Therapeutics Inc. distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Vuong Trieu, the company is applying AI, nanomedicine and innovative clinical approaches to reimagine biotechnology. Anchored by a strong intellectual property portfolio, including some 500 patent applications and 75 granted patents, Oncotelic is assembling a pioneering pipeline designed to transform how cancer and rare diseases are treated.
About Oncotelic Therapeutics Inc.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns
For further information, please visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
FAQ
What is Oncotelic Therapeutics (OTLC) main focus in drug development?
How many patents does Oncotelic Therapeutics (OTLC) currently have?
Who is the CEO of Oncotelic Therapeutics (OTLC)?
What technologies does Oncotelic Therapeutics (OTLC) use in its drug development?
What types of cancer is Oncotelic Therapeutics (OTLC) targeting?
